Core Viewpoint - The company is transferring 100% equity of Beijing Yihong Medical Technology Service Co., Ltd. to itself through its wholly-owned subsidiary, Yuchuang Investment (Hong Kong) Co., Ltd., for a transaction price of 346 million yuan [1] Group 1 - The transaction will result in the company directly holding 100% equity of Yihong Medical after the transfer is completed [1] - This equity change is part of an internal restructuring of the company's and its subsidiary's shareholding structure [1]

Core Insights - Health Catalyst (HCAT) reported revenue of $76.32 million for the quarter ended September 2025, showing no change compared to the same period last year, with EPS at $0.06, down from $0.07 year-over-year [1] - The revenue exceeded the Zacks Consensus Estimate of $75.08 million by +1.66%, and the EPS surpassed the consensus estimate of $0.05 by +20% [1] Revenue Breakdown - Professional services revenue was $24.27 million, exceeding the four-analyst average estimate of $23.08 million, but reflecting a year-over-year decline of -12.4% [4] - Technology revenue reached $52.05 million, slightly above the estimated $52 million, marking a +7% increase compared to the year-ago quarter [4] Profitability Metrics - Adjusted Gross Profit for Professional Services was $4.63 million, surpassing the average estimate of $4.45 million [4] - Adjusted Gross Profit for Technology was $35.5 million, exceeding the average estimate of $34.9 million [4] Stock Performance - Health Catalyst shares have returned +6.8% over the past month, outperforming the Zacks S&P 500 composite's +0.3% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]